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ABSTRACT
Introduction: Gastrointestinal angiodysplasias are an
important cause of difficult-to-manage bleeding,
especially in older patients. Endoscopic coagulation of
angiodysplasias is the mainstay of treatment, but may
be difficult for small bowel angiodysplasias because of
the inability to reach them for endoscopic intervention.
Some patients are red blood cell (RBC) transfusion
dependent due to frequent rebleeding despite
endoscopic treatment. In small cohort studies,
octreotide appears to decrease the number of bleeding
episodes in patients with RBC transfusion dependency
due to gastrointestinal angiodysplasias. This trial will
assess the efficacy of octreotide in decreasing the need
for RBC transfusions and parenteral iron in patients
with anaemia due to gastrointestinal bleeding of small
bowel angiodysplasias despite endoscopic intervention.
Study design: Randomised controlled, superiority,
open-label multicentre trial.
Participants: 62 patients will be included with
refractory anaemia due to small bowel angiodysplasias,
who are RBC transfusion or iron infusion dependent
despite endoscopic intervention and oral iron
supplementation.
Intervention: Patients will be randomly assigned (1:1)
to standard care or 40 mg long-acting octreotide once
every 4 weeks for 52 weeks, in addition to standard
care. The follow-up period is 8 weeks.
Main outcome measures: The primary outcome is
the difference in the number of blood and iron
infusions between the year prior to inclusion and the
treatment period of 1 year. Important secondary
outcomes are the per cent change in the number of
rebleeds from baseline to end point, adverse events
and quality of life.
Ethics and dissemination: The trial received ethical
approval from the Central Committee on Research
Involving Human Subjects and from the local
accredited Medical Research Ethics Committee of the
region Arnhem-Nijmegen, the Netherlands (reference
number: 2014-1433). Results will be published in a
peer-reviewed journal and presented at international
conferences.
Trial registration number: NCT02384122;
Pre-results.
INTRODUCTION
Angiodysplasias (ADs) are the most common
vascular anomalies of the gastrointestinal
tract and the second leading cause of
gastrointestinal bleeding in the elderly.1
The presentation extends from absence of
symptoms to occult and sometimes overt
gastrointestinal bleeding. Approximately 90%
of haemorrhagic ADs cease spontaneously,
but recurrence is high.2 The impact on the
patient may be large with a need for multiple
red blood cell (RBC) transfusions, frequent
hospitalisations and surgery.3 Decreased
Strengths and limitations of this study
▪ First randomised controlled trial that investigates
the efficacy of octreotide in gastrointestinal
angiodysplasias.
▪ The study has a clinical relevant end point with
an adequately powered sample size.
▪ Patient-reported outcome measurements are
incorporated.
▪ It is not a double-blind, placebo-controlled trial.
▪ The baseline transfusion requirements are retro-
spectively assessed.
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quality of life and the ﬁnancial burden on healthcare
systems are legitimate concerns.
There are different treatment options for symptomatic
ADs: (1) conservative management with iron supple-
mentation and, when necessary, RBC transfusions, (2)
endoscopic intervention with argon plasma coagulation
(APC), (3) radiological intervention with artery coiling,
(4) pharmacological therapies and (5) surgical resec-
tion. Endoscopic APC is the preferred treatment.
Recurrent bleeding rates in patients treated with APC
remain high, with rates up to 20% over a 2-year
follow-up.4–6 ADs located in the small bowel are asso-
ciated with an even high rebleeding rate, up to 45%.
This could be related to their relative inaccessibility with
standard endoscopy.7 As a result, some of these patients
develop refractory anaemia and become dependent on
symptomatic treatment with parenteral iron supplemen-
tation and RBC transfusions.
Determining the most effective pharmacological treat-
ment in these patients with small bowel AD-associated
refractory anaemia is challenging. Oestrogen and pro-
gesterone are not effective and while8–12 thalidomide
has been advocated for bleeding ADs, side effects are
considerable.13
Therapy with octreotide is promising, because of its
antiangiogenic properties, decrease in splanchnic blood
ﬂow and enhanced platelet aggregation.14 15 Moreover, it
is easy to use and has a relative mild side effect proﬁle.
There is limited evidence for the efﬁcacy of octreotide in
reducing AD bleeding.16–21 A non-randomised study
compared 32 refractory AD patients treated with octreo-
tide to an external placebo control group, which showed
a signiﬁcant decrease in rebleeding rate and need for
oral iron.16 Recently, a small randomised controlled trial
(RCT) was performed with the somatostatin analogue
pasireotide, with promising results.22 However, no statis-
tical difference in RBC transfusions was observed. Other
cohort studies showed a signiﬁcant decrease of more
than 50% in RBC transfusion requirements.17–21
Extrapolation of these results is difﬁcult in view of the
very small size of cohorts and absence of control groups.
We designed a randomised, open-label controlled trial
to evaluate the clinical efﬁcacy of octreotide. We hypothe-
sise that octreotide decreases the need for RBC transfu-
sions and iron supplementation in patients with refractory
anaemia due to small bowel ADs. The primary aim of this
study is to assess the efﬁcacy of octreotide to decrease the
RBC and iron transfusions in patients with refractory
anaemia due to small bowel ADs. Also, we determine if
octreotide decreases the number of rebleeds and assess
safety and cost-effectiveness compared with standard care.
METHODS AND ANALYSIS
Study design
We will conduct a phase III, randomised, open-label,
parallel-group, superiority, multicentre trial of standard
care plus octreotide, compared with standard care in 62
patients with anaemia despite endoscopic intervention
due to small bowel ADs (OCEAN). This protocol is
according to the standard protocol items for randomised
trials (SPIRIT) statement.
Study population
Patients older than 45 years that are diagnosed with
refractory anaemia due to small bowel ADs. Refractory
anaemia is deﬁned as a haemoglobin level of
<7.5 mmol/L with intravenous iron or blood transfusion
dependency despite ≥1 endoscopic intervention in the
year after diagnosis (or unsuitable for/refusing endos-
copy or surgery) and oral iron supplementation. It is
known that gastrointestinal AD is mostly a disease of the
elderly; younger patients with symptomatic AD might
have another aetiology (eg, Rendu-Osler-Weber).
Therefore, we exclude patients younger than 45 years, to
obtain a homogeneous patient group.
Inclusion criteria
▸ Older than 45 years;
▸ Proven small bowel ADs: single or multiple 2–5 mm
ﬂat bright red spots with round uniform or slightly
irregular margins; or lesions appearing as raised and
reddened areas with a distinctly irregular margin,
when larger than 5 mm; found during upper, lower
gastrointestinal endoscopy and video capsule or
enteroscopy;
▸ Intravenous transfusion dependency: at least four
blood transfusions and/or iron infusions in the year
before inclusion, despite an attempt to supplement
iron orally;
▸ Failure of endoscopic therapy: at least one endo-
scopic attempt to coagulate the ADs within the year
of diagnosis or unsuitable for/refusing endoscopy or
surgery;
▸ Able to provide informed consent (IC).
Exclusion criteria
▸ Liver cirrhosis Child-Pugh C, liver failure or diag-
nosed portal hypertension;
▸ Any other possible source of gastrointestinal bleeding
found during diagnostic endoscopy;
▸ Previous unsuccessful treatment with octreotide for
the same indication (refractory anaemia due to ADs);
▸ Current thalidomide treatment which is effective (no
parenteral iron or RBC transfusion dependency);
▸ Normalisation of haemoglobin level under oral iron
supplementation alone;
▸ Patients with chronic renal failure who have an esti-
mated glomerular ﬁltration rate (eGFR) <30 mL/min;
▸ Life expectancy <1 year;
▸ Patients with left ventricular assist devices;
▸ Hereditary haemorrhagic telangiectasia;
▸ Pregnant or nursing women;
▸ Uncontrolled diabetes as deﬁned by glycated haemo-
globin >64 mmol/mL, despite adequate therapy;
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▸ Hereditary haemorrhagic diseases or haematological
disorders with active treatment;
▸ Patients with a known hypersensitivity to somatostatin
analogues or any component of the octreotide
(Sandostatin) LAR formulations;
▸ Symptomatic cholecystolithiasis;
▸ Non-malignant medical illnesses that are uncon-
trolled or whose control may be jeopardised by the
treatment with this study treatment;
▸ Cancer currently undergoing chemotherapy or radi-
ation therapy.
Randomisation and treatment allocation
Patients will be randomised in a 1:1 ratio to receive
standard care or open-label octreotide plus standard
care for 1 year. Stratiﬁcation will be based on two vari-
ables with each of the two groups: (1) the use of anticoa-
gulants and platelet aggregation inhibitors versus no
anticoagulant drugs; (2) only iron infusion dependent
versus iron and blood infusion dependency. Therefore,
block randomisation will consist of block sizes of 4. The
trial is not blinded for patients and treating physicians,
but the outcome adjudication committee is.
A web-based patient randomisation service for clinical
trials will be used (Castor Electronic Data Collection
(EDC)). When the screening visit data are entered in
the electronical case record form (eCRF), and informa-
tion regarding use of anticoagulants and/or platelet
aggregation inhibitors is given, randomisation will be
performed.
Trial treatments
Octreotide
Patients in the intervention group will simultaneously
receive two injections of 20 mg Sandostatin LAR (octreo-
tide) intramuscular every 28 days on top of standard of
care. Treatment duration is 1 year with 2 months
follow-up for all patients. Long-acting octreotide (LAR
formulation) is chosen for patient comfort to only have
injections once monthly and thereby optimise patient
adherence. This dose is higher than existing evidence
on octreotide for this indication. The reason is that it is
still not proven with an RCT that samatostatin analogues
(SST) is effective in these patients and this is a
proof-of-principle study rather than a dose-ﬁnding study.
Moreover, for other indications, higher monthly dosages
of somatostatin analogues are more effective.23 24 When
patients develop severe but not life-threatening adverse
events (AEs; ie, grade 3; hospitalisation required or limi-
tation of patient’s ability to care for himself/herself), we
will reduce the dosage with 10 mg until AEs disappear.
When a grade 3 AE persists despite dosage reduction,
Sandostatin LAR will be discontinued. Those patients
will be followed after discontinuation and will not be
excluded from analyses. If patients are unresponsive to
octreotide (Sandostatin) LAR 40 mg monthly, we will
not increase the dose any further. Sandostatin LAR will
be administered at the patients’ home by experienced
nurses from Novanurses, a service provided by Eurocept
Homecare.
Standard care
To align clinical practices in the participating centres, a
standard of care protocol is developed to treat patients
similarly during the treatment phase of this trial. A
summary of this protocol is given below.
Anticoagulant therapy can be modiﬁed after randomi-
sation according to local practice of the attending phys-
ician and is registered as adjustment in the standard of
care. However, in most patients with such severe AD
bleeding, the option of withdrawal antiplatelet and/or
anticoagulant therapy would have been considered prior
to entry in the trial.
The ﬁrst choice of therapy is oral iron supplementation
and must be initiated prior to starting parenteral iron as
maintenance therapy. When oral iron is insufﬁcient and
iron deﬁciency anaemia persists, parenteral iron may be
administered (maximum 20 mg/kg bodyweight).
RBC transfusion is only indicated when anaemia per-
sists despite parenteral iron supplementation. A distinc-
tion is made between patients with and without
haemodynamic instability:
▸ Occult gastrointestinal bleed or acute gastrointestinal
bleed without haemodynamic instability: RBC transfu-
sion is given following the ‘4-5-6’ rule (see online sup-
plementary additional ﬁle 1) or when symptoms
associated with anaemia arise.25
▸ Acute gastrointestinal bleed with haemodynamic
instability: haemoglobin target value >5.0 mmol/L.26
In case of symptoms of hypoxia, the target value is
>6 mmol/L.
Study procedures
This study consists of seven visits including one screen-
ing visit, ﬁve visits during treatment and one follow-up
visit (ﬁgure 1). Data will be collected into an eCRF
(Castor) designed to capture all visit information includ-
ing medical history, results from laboratory analysis and
AEs. The study duration for all patients is 60 weeks in
total, divided into a screening phase, a 52-week treat-
ment phase and a 8-week follow-up phase (ﬁgure 1). At
screening, each participant will be screened for eligibil-
ity after written IC is obtained. In women with childbear-
ing potential, a pregnancy test is performed. Within the
treatment phase of the trial, patients are seen at weeks
0, 4, 16, 28 and 52. One week after the ﬁrst injection,
the patient will receive a phone call to assess AEs. The
follow-up visit takes place 2 months after the octreotide
concentration is below therapeutic doses, which is
8 weeks after the last treatment phase visit. This study
visit aims to detect late AEs rather than establish the
long-term effect of octreotide after discontinuation.
During each visit, medical history, medication use, AEs,
tolerability and drug accountability are assessed. In addi-
tion, a physical examination is performed and blood
samples are drawn. Glucose, liver enzymes and lipid
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proﬁle are checked to assess the possible side effects of
octreotide. Patients have to ﬁll out two questionnaires
(SF-36 and PSQ-An) three times, that is, at the start
(week 0) and end of treatment (week 52), and at
follow-up (week 60). The requested parameters at the
different visits are listed below:
Screening visit
▸ Written IC
▸ Eligibility criteria check
▸ General AD characteristics
▸ Pregnancy test in premenopausal females.
Baseline, end of treatment and follow-up visit
▸ 36-item short form survey (SF-36) questionnaire:
quality of life
▸ PSQ-An questionnaire: patient satisfaction question-
naire for anaemia treatment.
Every visit
▸ AEs;
▸ Concomitant therapy;
▸ Drug accountability;
▸ Physical examination, including vital signs and weight;
▸ Laboratory tests: haematology (haemoglobin, haemoto-
crit, leucocytes, platelets, absolute neutrophil count,
prothrombin time), biochemistry (serum iron, ferritin,
transferring and transferring saturation, calcium, phos-
phate, glucose, alanine aminotransferase, aspartate ami-
notransferase, total bilirubin, γ-glutamyl transpeptidase,
alkaline phosphatase, albumin, creatinine) and lipid
proﬁle (total cholesterol, high-density lipoprotein
(HDL), low-density lipoprotein (LDL), triglycerides).
Study end points
Primary outcome
The mean/median difference in blood and parenteral
iron requirements between the 1 year prior to inclusion
and the treatment period of 1 year compared between
the intervention and control arm. All blood transfusions
that are given with another indication than gastrointes-
tinal blood loss are registered, but excluded for analysis
for the primary outcome.
Secondary outcomes
▸ The percentual decrease in blood and iron require-
ments between the year prior to inclusion and the
treatment period of 1 year in the intervention arm
compared with the control group;
▸ Percentage of haemoglobin increase from baseline
until end of treatment for patients treated with
octreotide compared with the control group;
▸ The mean difference in haemoglobin level from base-
line until end of treatment for patients treated with
octreotide compared with the control group;
▸ Number of patients requiring RBC transfusions from
baseline until end of treatment for patients treated
with octreotide compared with the control group;
▸ Number of patients requiring other transfusions or
medication to correct coagulation between baseline
until end of treatment for patients treated with
octreotide compared with the control group;
▸ The change in number and severity of bleeding epi-
sodes between start and end of treatment for patients
treated with octreotide compared with the control
group;
▸ The change in number of patients free of rebleeding
between start and end of treatment for patients treated
with octreotide compared with the control group;
▸ Reduction in oral iron requirement between start and
end of treatment for patients treated with octreotide
compared with the control group;
▸ The change in level of serum ferritin between base-
line until end of treatment for patients treated with
octreotide compared with the control group;
▸ The number and type of AEs (cardiac, pulmonary,
neurological, other) between the control and treat-
ment arms during the treatment period;
▸ Difference in number of hospitalisations, intensive
care unit admissions and duration of hospitalisation
between the control and treatment arms during the
treatment period;
▸ The need for rescue therapy using APC, coiling or
surgery compared between the control and treatment
arms during the treatment period;
▸ Change in quality of life as measured by SF-36 between
baseline and end of treatment for patients treated with
octreotide compared with the control group;
Figure 1 Study design of the
OCEAN trial. IC, informed
consent; PL, physical
examination, laboratory tests,
safety assessment; Q,
assessment of PSQ-An and
SF-36 questionnaires.
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▸ Mortality and cause of death compared between the
control and treatment arms during the treatment
period.
Study withdrawal
Participants can withdraw IC and leave the study at any
time. The investigator will withdraw a participant from
the study for any of the following reasons: pregnancy,
consistent failure to adhere to protocol requirements,
unacceptable toxicity of study medication, surgical inter-
ventions during the study or any other reason in the
best interest of the patient. In case of withdrawal by the
physician, all data generated from the study will be ana-
lysed and the reason(s) for discontinuation will be
recorded.
Sample size considerations
We aim to analyse 56 patients based on a sample size cal-
culation with 80% power to detect a difference of two
RBC transfusions or iron infusions in 1 year. This
accounts for an expected decrease of two transfusions in
the intervention arm and no decrease in the control
arm, with an estimated SD of 2.6 and a signiﬁcance level
of 0.05 using a Mann-Whitney U test. The estimated
mean difference is based on the ﬁve available prospec-
tive cohort studies at the time of designing the study
and the difference in blood transfusion requirements
before and after treatment with octreotide.16–20 Those
studies show a decrease of more than 50% of the blood
transfusion requirements. We estimate a baseline depend-
ency of four blood or iron transfusions in the last year, as
this is intermediate of the studies of Junquera et al16
(1.1), Scaglione et al17 (3.6), Nardone et al18 (8.8) and
Bon et al20 (10). A transfusion difference of 2 units is clin-
ically relevant, which is in the same vein as a recent
meta-analysis that detected a mean difference of 2.2
units.27 The SD of 2.6 is derived from the study of
Junquera et al.16 Taking into account a dropout rate of
10%, the total sample size has to be 62 for the complete
cohort with 31 patients in each treatment group.
Data management
All data are entered electronically according to Good
Clinical Practice in the data management system Castor
EDC at the participating site where the data are origi-
nated. Checks will be applied at the time of data entry
into a speciﬁc ﬁeld and/or before the data are written
(committed) to the database. Modiﬁcations in the data-
base will be documented through either the data change
system or an inquiry system. Data are retrievable for
viewing through the data entry applications. The type of
activity that an individual user may undertake is regulated
by the privileges associated with his/her user identiﬁca-
tion code and password. A complete back-up of the data-
base is regularly performed. After study completion, the
data will be locked and transferred to SPSS. Data are
stored for at least 15 years after study completion.
Statistical analysis
Each patient who received at least one injection of
Sandostatin LAR or has been included in the observa-
tional arm for 1 month will be included in the
intention-to-treat analysis. Parallel analyses will be per-
formed on the per-protocol population. The per-
protocol population is deﬁned as all patients who have
received at least 80% of the total amount of dosages of
octreotide at 52 weeks from baseline.
Data on demographic and baseline characteristics will
be summarised for continuous variables, depending on
distribution, and values will be presented as mean±SD
or as median±IQR. Discrete variables (eg, sex) will be
summarised by proportions (percentages). Differences
between the intervention and standard of care will be
analysed using Student’s t-test for normally distributed
data or the Mann-Whitney U test for non-normally dis-
tributed data. Pearson’s χ2 test will be used to compare
dichotomised outcomes between the two arms.
Frequency tables will be compiled for (serious) AEs clas-
siﬁed according to the standard WHO—Adverse
Reaction Terminology (WHO-ART) Body System
Dictionary and preferred terms. All statistical analyses
will be two-sided with a critical signiﬁcance level of 5%.
Missing data and loss to follow-up will be reported as
percentage and, if known, the reason will be reported.
Analyses will be performed with IBM SPSS Statistics
V.22.0 (SPSS, Chicago, Illinois, USA).
Subgroup analysis will be performed for stratiﬁed vari-
ables: (1) use of anticoagulants, (2) iron infusion or
iron and blood transfusion dependent. The SF-36 will be
used to calculate quality-adjusted life years to determine
cost-effectiveness.
Monitoring
Site monitoring
Two independent monitors of St Antonius Hospital will
visit the sites to review the records, compare with source
documents, and observe and discuss the conduct of the
trial with the investigators and site coordinator. The
monitors are responsible for monitoring adherence to
the protocol and guidelines, as well as ensuring comple-
tion of the eCRF and other documentation. In order to
ensure the accuracy of data, the monitors, regulatory
agencies and members of the Steering Committee have
direct access to source documents. Anonymity of partici-
pants will be maintained at all times.
Trial monitoring
An independent Data Safety Monitoring Board (DSMB)
will meet periodically to monitor the safety and progres-
sion of the trial. The responsibilities and procedures of
the board are included in a DSMB Charter. Once 31
participants have completed the trial, an interim analysis
of effectiveness and safety end points will be performed.
The DSMB may recommend continuing the trial, early
termination of the trial or modiﬁcation of the trial. A
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recommendation to terminate the trial early will only be
made if there is clear evidence of a clinically important
beneﬁcial or harmful effect.
Ethics and dissemination
Ethical considerations
Ethical approval of the study protocol was given by the
Central Committee on Research Involving Human
Subjects and by the local accredited Medical Research
Ethics Committee of the region Arnhem-Nijmegen, the
Netherlands (reference number: 2013/354). An inde-
pendent DSMB has been constituted to monitor patient
safety and treatment efﬁcacy during the trial.
Dissemination plan
Data from all centres will be analysed together and pub-
lished as soon as possible. Individual participants may
not publish data concerning their patients that are
directly relevant to questions posed by the trial until the
sponsor has published its report. The sponsor will have
access to the ﬁnal data set, form the basis of the Writing
Committee and advise on the nature of publications.
The trial will be presented at regional and national con-
ferences. The ﬁnal results will be presented at scientiﬁc
meetings and published in a peer-reviewed journal
(authorship will be according to the journal’s
guidelines).
DISCUSSION
The OCEAN study is the ﬁrst to prospectively investigate
the efﬁcacy of octreotide in patients with small bowel
AD-associated refractory anaemia in an RCT. It is designed
to determine whether and to what extent octreotide treat-
ment can decrease parenteral iron and RBC transfusion
requirements. This trial has a relevant clinical end point,
that is, 50% reduction in parenteral iron and/or RBC
transfusions, with an adequate powered sample size. A stat-
istically signiﬁcant outcome has direct implications for
current practice of patients with refractory anaemia due to
gastrointestinal ADs. Furthermore, this design provides an
opportunity to study the safety of octreotide in a monthly
dose of 40 mg in patients with ADs. Finally, we incorporate
patient-reported outcome measurements to investigate the
effect of octreotide on quality of life and cost-effectiveness.
A retrospective study suggests that octreotide LAR treat-
ment is cost-effective in these patients,28 but no previous
studies evaluated treatment of ADs from the most import-
ant perspective: the patient’s perspective.
Some possible concerns need to be addressed. First,
although a double-blind, placebo-controlled designed
trial would have been superior in minimising the chance
of information bias, an advantage of this current design
is that it resembles the effect in clinical practice more
after implementation of the intervention in comparison
to a blinded trial.29 Second, the primary outcome at
baseline (parenteral iron and RBC transfusion require-
ments before start of treatment phase) is determined
retrospectively in both groups, which could lead to
regression to the mean and information bias. However,
comparing the outcomes between the two groups
should wash out any effect of regression to the mean.
We think the risk of information bias as a consequence
of the retrospective retrieval is low due to the fact that
parenteral iron administration or RBC transfusion must
be registered and therefore retrievable in the patient’s
electronic record. Third, with other somatostatin analo-
gues (eg, pasireotide), intramuscular use could cause
haematomas, especially in patients on anticoagulants.
This might lead to a reduction in injections compared
with the protocol and could inﬂuence the results.
Fourth, the strict inclusion and exclusion criteria will
slow down our inclusion rate with possible delay in
gaining the ﬁnal results. Finally, we did not stratify for
any possible differences between centres. Owing to the
small number of patient inclusions per centre, centre
stratiﬁcation might lead to more unbalanced randomisa-
tion than it would correct for an inﬂuence due to differ-
ences in practice.
Despite these concerns, our study will add signiﬁcant
value to the existing body of literature on treatment of
patients with refractory anaemia resulting from small
bowel ADs bleeds. The rigorous design of the OCEAN
trial will address the efﬁcacy of octreotide in
therapy-resistant anaemia from small bowel ADs.
Trial status
The Medical Ethics Committee of the Radboud
University Medical Center Nijmegen approved the
protocol in August 2015. Patient recruitment started in
September 2015.
By the medical ethical committee approved amendment
Inclusion criteria
▸ ADs at any location in the gastrointestinal tract,
which are transfusion dependent and fail endoscopic
therapy;
▸ Owing to the broadening in localisation of the ADs, it
is not always necessary to perform a video capsule
endoscopy.
Exclusion criteria
Patients with chronic renal failure who have a
eGFR<30 mL/min is removed as exclusion criterion.
Study procedures
▸ The PSQ-An questionnaire is replaced for the vali-
dated Multidimensional Fatigue Inventory (MFI-20);
▸ Physical examination is only performed at the base-
line, visit T28 and end of study visit;
▸ No blood samples are taken at the follow-up visit
(week 60);
▸ The following laboratory tests are not measured: hae-
motocrit, absolute neutrophil count, prothrombin
time, transferring, calcium, phosphate, alanine trans-
aminase, cholesterol (total, HDL, LDL), triglycerides.
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